Difference between revisions of "Template:Antiarrhythmic agents"
Jump to navigation
Jump to search
blackwiki>DePiep m (rm Mednav index templates. See talk (via AWB script)) |
m (67 revisions imported) |
||
| (4 intermediate revisions by 4 users not shown) | |||
| Line 6: | Line 6: | ||
|group1 = [[Channel blocker]]s | |group1 = [[Channel blocker]]s | ||
| − | |list1 = {{Navbox subgroup | + | |list1 = {{Navbox|subgroup |
| group1 = [[Antiarrhythmic agent#Class I agents|class I]]<BR>([[sodium channel blocker|Na<sup>+</sup> channel blockers]]) | | group1 = [[Antiarrhythmic agent#Class I agents|class I]]<BR>([[sodium channel blocker|Na<sup>+</sup> channel blockers]]) | ||
| − | | list1 = {{Navbox subgroup | + | | list1 = {{Navbox|subgroup |
| group1 = class Ia ([[Cardiac action potential#Phase 0|Phase 0]]→ and [[Cardiac action potential#Phase 3|Phase 3]]→) | | group1 = class Ia ([[Cardiac action potential#Phase 0|Phase 0]]→ and [[Cardiac action potential#Phase 3|Phase 3]]→) | ||
| Line 15: | Line 15: | ||
* [[Ajmaline]] | * [[Ajmaline]] | ||
* [[Disopyramide]] | * [[Disopyramide]] | ||
| + | * [[Dihydroquinidine|Hydroquinidine]] | ||
* [[Lorajmine]] | * [[Lorajmine]] | ||
* [[Prajmaline]] | * [[Prajmaline]] | ||
| Line 23: | Line 24: | ||
| group2 = class Ib ([[Cardiac action potential#Phase 3|Phase 3]]←) | | group2 = class Ib ([[Cardiac action potential#Phase 3|Phase 3]]←) | ||
| list2 = | | list2 = | ||
| − | * ''[[Intravenous therapy|IV]]'' | + | * ''[[Intravenous therapy|IV]]'' |
| − | * ''[[enteral]]'' | + | ** [[Lidocaine]]<sup>#</sup> |
| − | * [[Mexiletine]] | + | * ''[[enteral]]'' |
| − | * [[Tocainide]] | + | ** [[Aprindine]] |
| + | ** [[Mexiletine]] | ||
| + | ** [[Tocainide]] | ||
| group3 = class Ic ([[Cardiac action potential#Phase 0|Phase 0]]→) | | group3 = class Ic ([[Cardiac action potential#Phase 0|Phase 0]]→) | ||
| Line 63: | Line 66: | ||
|group2 = [[Receptor (biochemistry)|Receptor]] [[agonist]]s<BR>and [[Receptor antagonist|antagonist]]s | |group2 = [[Receptor (biochemistry)|Receptor]] [[agonist]]s<BR>and [[Receptor antagonist|antagonist]]s | ||
| − | |list2 = {{Navbox subgroup | + | |list2 = {{Navbox|subgroup |
| group2 = [[Antiarrhythmic agent#Class II agents|class II]]<br/>([[Cardiac action potential#Phase 4|Phase 4]]→, [[beta blocker|β blocker]]s) | | group2 = [[Antiarrhythmic agent#Class II agents|class II]]<br/>([[Cardiac action potential#Phase 4|Phase 4]]→, [[beta blocker|β blocker]]s) | ||
| Line 70: | Line 73: | ||
* [[Pindolol]] | * [[Pindolol]] | ||
* [[Propranolol]] | * [[Propranolol]] | ||
| − | * ''cardioselective'' | + | * ''cardioselective'' |
| − | * [[Atenolol]] | + | ** [[Acebutolol]] |
| − | * [[Esmolol]] | + | ** [[Atenolol]] |
| − | * [[Metoprolol]] | + | ** [[Esmolol]] |
| + | ** [[Metoprolol]] | ||
| group5 = [[adenosine A1 receptor|A<sub>1</sub> agonist]] | | group5 = [[adenosine A1 receptor|A<sub>1</sub> agonist]] | ||
| Line 97: | Line 101: | ||
| group8 = [[Ion transporter]]s | | group8 = [[Ion transporter]]s | ||
| − | | list8 = {{Navbox subgroup | + | | list8 = {{Navbox|subgroup |
| group1 = [[Na+/K+-ATPase|Na<sup>+</sup>/ K<sup>+</sup>-ATPase]] | | group1 = [[Na+/K+-ATPase|Na<sup>+</sup>/ K<sup>+</sup>-ATPase]] | ||
| list1 = | | list1 = | ||
| + | * [[Digitoxin]] | ||
* [[Digoxin]] | * [[Digoxin]] | ||
| + | * [[Ouabain]] | ||
}} | }} | ||
Latest revision as of 14:15, 22 October 2020
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{Antiarrhythmic agents|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{Antiarrhythmic agents|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{Antiarrhythmic agents|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.